National Cancer Institute; Notice of Closed Meeting, 22165 [2024-06744]
Download as PDF
<![CDATA[
22165
Federal Register / Vol. 89, No. 62 / Friday, March 29, 2024 / Notices
including FTCA coverage; and free
clinics that seek to sponsor individuals
for deemed PHS employee status for
purposes of eligibility for liability
protections, including FTCA coverage.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
Number of
respondents
Form name
Application for Health Center Program Recipients for
Deemed PHS Employment with Liability Protections
Under the FTCA ...............................................................
Application for Deemed Health Center Program Recipients
to Sponsor Volunteer Health Professionals for Deemed
PHS Employment with Liability Protections Under the
FTCA ................................................................................
Volunteer Health Professionals Emergency Deeming
Sponsorship Application ...................................................
Application for Free Clinics to Sponsor Individuals for
Deemed PHS Employment with Liability Protections
Under the FTCA ...............................................................
Total ..............................................................................
Maria G. Button,
Director, Executive Secretariat.
Number of
responses per
respondent
1,160
2.5
2,900
1,156
3
3,468
2.0
6,936
60
1
60
1.0
60
374
3
1,122
2.0
2,244
2,750
........................
5,810
........................
12,140
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Indian Health Service
Change in Publication Policy of
Notices of Funding Opportunity
khammond on DSKJM1Z7X2PROD with NOTICES
Per the current policy of the
Department of Health and Human
Services, the Indian Health Service
(IHS) will begin using Grants.gov as the
primary publication outlet for IHS
Notices of Funding Opportunity
(NOFO), as of February 1, 2024. Links
to the announcement in Grants.gov and
to the NOFO will be posted to the IHS
Division of Grants Management website,
at https://www.ihs.gov/dgm/funding/.
Any questions regarding this change
should be directed to the Division of
Grants Management by email to DGM@
ihs.gov.
Roselyn Tso,
Director, Indian Health Service.
[FR Doc. 2024–06679 Filed 3–28–24; 8:45 am]
BILLING CODE 4166–14–P
VerDate Sep<11>2014
16:49 Mar 28, 2024
Jkt 262001
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
PO 00000
Frm 00050
Total burden
hours
1
[FR Doc. 2024–06687 Filed 3–28–24; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Average
burden per
response
(in hours)
Total
responses
1,160
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4165–15–P
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
Total Estimated Annualized Burden
Hours:
Fmt 4703
Sfmt 4703
Name of Committee: National Cancer
Institute Special Emphasis Panel; FEB2024
Cycle 46 NExT SEP Committee Meeting.
Date: May 7, 2024.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Room 3A44,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Persons: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, Maryland
20817, 301–496–4291, mroczkoskib@
mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary,
Development Experimental Therapeutics
Program, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 3W110,
Rockville, Maryland 20850, 240–276–5683,
toby.hecht2@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: March 26, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–06744 Filed 3–28–24; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\29MRN1.SGM
29MRN1
]]>Agencies
[Federal Register Volume 89, Number 62 (Friday, March 29, 2024)]
[Notices]
[Page 22165]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06744]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for the treatment of cancer. The outcome of the evaluation will provide
information to internal NCI committees that will decide whether NCI
should support requests and make available contract resources for
development of the potential therapeutic to improve the treatment of
various forms of cancer. The research proposals and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; FEB2024 Cycle 46 NExT SEP Committee Meeting.
Date: May 7, 2024.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program
Portfolio.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, Room 3A44, Bethesda, Maryland 20892 (Virtual Meeting).
Contact Persons: Barbara Mroczkowski, Ph.D., Executive
Secretary, Discovery Experimental Therapeutics Program, National
Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda,
Maryland 20817, 301-496-4291, [email protected].
Toby Hecht, Ph.D., Executive Secretary, Development Experimental
Therapeutics Program, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 3W110, Rockville, Maryland 20850, 240-276-5683,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: March 26, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-06744 Filed 3-28-24; 8:45 am]
BILLING CODE 4140-01-P
